SAGE Therapeutics (NASDAQ:SAGE) reported Q1 net loss of $122.1 million. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $3.21 million.
SAGE Therapeutics (NASDAQ:SAGE) reported Q1 net loss of $122.1 million. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $3.21 million.